Skip to main content

Table 2 Evidence implicating Fyn in amyloid-beta oligomer action of Alzheimer’s disease

From: Fyn kinase inhibition as a novel therapy for Alzheimer’s disease

Observation

Detail

References

Increased Fyn in AD

Co-localized with Tau

[29]

Amyloid-beta activates Fyn

Oligomer specific and PrP mediated

[14]

Fyn impairs synapse

N-methyl-d-aspartate receptor and dendritic spine loss

[24]

Fyn interacts with Tau

Localizes and phosphorylates Tau

[6163]

Fyn alters AD transgenics

Fyn loss protects and Fyn gain accelerates

[61, 64, 65]

  1. AD, Alzheimer’s disease; PrP, prion protein.